Make scientific figures in minutes
Create publication-quality figures with pre-made icons and templates, all from BioRender's web-based software
Use Icons In The App
Try a synonym, or sign up to request an icon from the app.
Autoinjector (Risankizumab)
[{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51522/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51522/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51523/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51523/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51524/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51524/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51525/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51525/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51526/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51526/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51527/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51527/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51528/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51528/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51529/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51529/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152a/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152a/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152b/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152b/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152c/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152c/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152d/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152d/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152e/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152e/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152f/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152f/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51530/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51530/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51531/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51531/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51532/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51532/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51533/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51533/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51534/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51534/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51535/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51535/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51536/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51536/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51537/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51537/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51538/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51538/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51539/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51539/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153a/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153a/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153b/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153b/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153c/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153c/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153d/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153d/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153e/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153e/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153f/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153f/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51540/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51540/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51541/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51541/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51542/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51542/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51543/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51543/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51544/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51544/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51545/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51545/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51546/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51546/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51547/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51547/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51548/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51548/667b173004e4d095b4c514f1.png"}]
Use this icon in BioRender along with 1000s of others to make your next science figure in minutes
.png)
SIGN UP FREEKeywords
Skyrizi,Plaque psoriasis,psoriatic arthritis,Crohn's disease,interleukin 23A,IL-23A,IL-23,cho cell,mutation,mutant,mutated,Leu234Ala,Leu235Ala,lala mutation,double mutation,subcutaneous injection,injection,autoinjection,monoclonal antibody,antibody,antibody drug,antibody drug,drug,antigen,competitor,immunologlobulin,binding agent,monoclonal,immune,immunoglobin,immunological,antigen-binding,nanobody,fabs,neutralizing,polyclonal,therapeutic,immunology,oncology,biochemistry,molecular biology,pharmacology,biotechnology,injector,auto injector,auto-injector,autoinjector,injector device,injector pen,inject,auto syringe,self-injectable,injectable,medication pen,medication,pen,uncapped,needle,metabolic,syndrome,treatment,treat,therapy,tip,medicine,plunger,dose window,selection,dial,dose,disposable,button,chemotherapy,chemo,cancer,at-home,one-use,spring-loaded syringes,syringe,actuator,self-administration,drug delivery,prefilled syringe,intramuscular,subcutaneous,single use,epinephrine,insulin pen,portable injector,Humira,rheumatoid arthritis,psoriasis,Crohn's disease,epipen,medical device,medical equipment,medical instrument,medical apparatus,medical tool,medical appliance,proj-creative-abx-24q2,proj-creative-abx-24q2-AbbVie,Skyrizi,risankizumab,injector pen
Image types
BioRender icons and templates meet journal, grant, and copyright standards. For AI-generated figures, policies vary. Learn More
Related Categories
Join 1,500,000 other scientists on BioRender
Sign up for your free account and start creating scientific figures faster today
FAQs
What is BioRender?
Can I use this icon in a BioRender figure or scientific illustration?
